| Identification | Back Directory | [Name]
Camidanlumab | [CAS]
921618-45-3 | [Synonyms]
Camidanlumab
Research Grade Camidanlumab
Research Grade Camidanlumab(DHB95803) |
| Hazard Information | Back Directory | [Uses]
Camidanlumab (HuMax-TAC) is a CD25 monoclonal antibody. Camidanlumab targets the cell-surface antigen CD25, which is over-expressed on a variety of hematological tumors and shows limited expression on normal tissues. Camidanlumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including lymphoma and leukemia[1]. | [References]
[1] Michael J Flynn, et al. ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. Mol Cancer Ther. 2016 Nov;15(11):2709-2721. DOI:10.1158/1535-7163.MCT-16-0233 |
|
|